# Sunitinib in Treating Patients With Relapsed Multiple Myeloma

> **NCT00514137** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 13 (actual)

## Conditions studied

- Refractory Multiple Myeloma
- Stage I Multiple Myeloma
- Stage II Multiple Myeloma
- Stage III Multiple Myeloma

## Interventions

- **DRUG:** sunitinib malate

## Key facts

- **NCT ID:** NCT00514137
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09
- **Primary completion:** 2009-03
- **Final completion:** 2010-08
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2014-05-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00514137

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00514137, "Sunitinib in Treating Patients With Relapsed Multiple Myeloma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00514137. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*